TSRL, Inc.’s Microarray Patch (MAP) of Trospium Chloride for Overactive Bladder Disease Continues Development with Grant from the NIH

TSRL, Inc., a privately-held preclinical accelerator, has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institute of Health (NIH) for about $300,000 over 12 months.

TSRL, Inc. will continue to broaden its MAP portfolio with the development of a once-a-week patch of Trospium Chloride (TC) optimized for improved tolerance and patient outcomes in overactive bladder (OB) disease.

OB is a disease that afflicts both men and women and is driven by the aging population with a prevalence estimated as high as 39% in the US and 45% for all women over 65. OB is accompanied by a significant loss of quality of life with documented increases in patient falls, anxiety, and depression. Muscarinic antagonists (anticholinergics) are currently the primary drugs used for treatment, but these agents are associated with numerous side effects, variable effectiveness and drug-drug interactions leading to discontinuation of therapy in over 50% of patients in 6-12 months. Furthermore, with age there is a growing concern for anticholinergic drug overload (especially due to drug-drug interactions) leading to additional effects such as cognition impairment and other CNS affects.

TSRL’s CEO Elke Lipka, PhD, MBA is highly enthusiastic about the patch approach for treating OB:

“Dosing regimen and therapeutic outcomes of TC in OB are suboptimal, mainly driven by poor and highly variable oral bioavailability, rather than the therapeutic effectiveness of TC. Our once weekly TC MAP will ensure patient compliance both via the delivery approach, and through better therapeutic outcomes.”

About TSRL, Inc.:

TSRL, Inc. is a preclinical biotech accelerator. We collaborate with partners in academia and industry to develop early-stage anti-infective therapeutics and drug delivery technologies. In these collaborations, we provide infrastructure, drug development expertise, and access to non-dilutive funding. Our portfolio holds promising lead-stage anti-infective therapeutics. We are actively looking for new technologies and strategic partnerships. More information about TSRL, Inc. and portfolio technologies are available at http://www.tsrlinc.com or can be requested by contacting Elke Lipka, CEO, elipka@tsrlinc.com